Alpha Sense BI

AUGUST 30, 2023

Research shows that the AI in asset management market will grow at a staggering 34% CAGR through 2027. The time is now to invest in a market intelligence platform with AI search capabilities, so you can speed up your research and outperform the market. Artificial intelligence is the only way to do it.

Management 98

Management Biotech Due Diligence Algorithm 98

Alpha Sense BI

MAY 28, 2024

Below, we explore the factors constraining venture capital funding into the first half of the year, and the ways investors can leverage crucial market intelligence to gain a competitive advantage in the shifting landscape. The VC Funding Dryspell Venture capital investment fell to the lowest activity in nearly five years for Q1 2024.

Capital 69

Capital Startups Biotech Due Diligence 69

Alpha Sense BI

APRIL 29, 2024

Traditional due diligence for start-up investors has historically been riddled with inefficiencies—tying up resources to sort through countless documents and copious amounts of data, and manually crafting market comparisons and performance. The renewable energy sub-sector is also seeing promising activity.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

APRIL 19, 2024

AlphaSense is a leading provider of market intelligence , including 10,000+ high-quality content sources from more than 1,500 leading research providers—all in a single platform. That’s why you need a tool that does all the heavy lifting for you, so you can focus on leveraging and analyzing information rather than searching for it.

Technology 69

Technology Technology Retail Biotech 69

Alpha Sense BI

APRIL 12, 2024

AlphaSense, a leading artificial intelligence (AI)-based market intelligence platform , offers proprietary Expert Insights through its extensive expert transcript library and Expert Call Services. With a doctor, I’m more interested in what treatments are you using.

Primary Research 52

Primary Research Advantage Advantage Research 52

Alpha Sense BI

MARCH 13, 2024

billion acquisition of Carmot Therapeutics, a clinical-stage biotechnology company with three GLP-1 assets in clinical production, including its CT-388 lead GLP-1 asset, in the hopes of gaining a competitive footing among Novo Nordisk and Eli Lilly’s products currently on the market (Ozempic, Wegovy, and Mounjaro, respectively).

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59